LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)

European Journal of Cancer

Volumn 45, Issue 10, 2009, Pages 1807-1814

  Agarwala, Sanjiv S ^a   Keilholz, Ulrich ^b   Gilles, Erard ^c   Bedikian, Agop Y ^d   Wu, Jane ^c   Kay, Richard ^e   Stein, Cy A ^f   Itri, Loretta M ^c   Suciu, Stefan ^g   Eggermont, Alexander M M ^h  

^a St Luke's Cancer Center   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c Genta Inc   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Rkstatistics   (United Kingdom)

^f ALBERT EINSTEIN CANCER CENTER   (United States)

^g EORTC DATA CENTER   (Belgium)

^h ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Dacarbazine; EORTC 18951; GM301; LDH; Melanoma; Oblimersen; Prognostic factors; Survival

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; LACTATE DEHYDROGENASE; OBLIMERSEN;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FOLLOW-UP STUDIES; HUMANS; L-LACTATE DEHYDROGENASE; LIVER NEOPLASMS; MELANOMA; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; THIONUCLEOTIDES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 67249148924     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.04.016     Document Type: Article

References (26)

1. Homsi J., Kashani-Sabet M., Messina J.L., and Daud A. Cutaneous melanoma: prognostic factors. Cancer Contr 12 (2005) 223-229
2. Buzaid A.C., and Anderson C.M. The changing prognosis of melanoma. Curr Oncol Rep 2 (2000) 322-328
3. Linette G.P., Carlson J.A., Slominski A., Mihm M.C., and Ross J.S. Biomarkers in melanoma: stage III and IV disease. Expert Rev Mol Diagn 5 (2005) 65-74
4. Petro A., Schwartz J., and Johnson T. Current melanoma staging. Clin Dermatol 22 (2004) 223-227
5. Sirott M.N., Bajorin D.F., Wong G.Y.C., et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 72 (1993) 3091-3098
6. Eton O., Legha S.S., Moon T.E., et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16 (1998) 1103-1111
7. Franzke A., Probst-Kepper M., Buer J., et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 78 (1998) 40-45
8. Proebstle T.M., Fuchs T., Scheibenbogen C., Sterry W., and Keilholz U. Long-term outcome of treatment with dacarbazine, cisplatin, interferon-α, and intravenous high dose interleukin-2 in poor risk melanoma patients. Melanoma Res 8 (1998) 557-563
9. Manola J., Atkins M., Ibrahim J., and Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group Trials. J Clin Oncol 18 (2000) 3782-3793
10. Banfalvi T., Boldizsar M., Gergye M., et al. Comparison of prognostic significance of serum 5-S-cysteinyldopa, LDH and S-100B protein in stage III-IV malignant melanoma. Pathol Oncol Res 8 (2002) 183-187
11. Keilholz U., Martus P., Punt C.J.A., et al. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomized EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin-2 (IL-2) with or without cisplatin. Eur J Cancer 38 (2002) 1501-1511
12. Smit L.H.M., Korse C.M., Hart A.A.M., et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 41 (2005) 386-392
13. Tas F., Oguz H., Argon A., et al. The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma. Med Oncol 22 (2005) 241-246
14. Balch C.M., Soong S.-.J., Atkins M.B., et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54 (2004) 131-149
15. Kounalakis N., and Goydos J.S. Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management. Curr Oncol Rep 7 (2005) 377-382
16. Fantin V.R., St-Pierre J., and Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9 (2006) 425-434
17. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 89 (2003) 877-885
18. Koukourakis M.I., Giatromanolaki A., Sivridis E., Gatter K.C., and Harris A.L. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway - a report of the Tumour Angiogenesis Research Group. J Clin Oncol 24 (2006) 4301-4308
19. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
20. Eggermont A.M.M., and Kirkwood J.M. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?. Eur J Cancer 40 (2004) 1825-1836
21. Bedikian A.Y., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24 (2006) 4738-4745
22. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
23. Keilholz U., Suciu S., Bedikian A.Y., et al. LDH is a prognostic factor in stage IV melanoma patients (pts) but is a predictive factor only for bcl2 antisense treatment efficacy: re-analysis of GM301 and EORTC 18951 randomized trials. J Clin Oncol 25 (2007) 485s [Suppl.; abstr 8552]
24. Keilholz U., Punt C.J.A., Gore M., et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized Phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 23 (2005) 6747-6755
25. Greenland S. Analysis of polytomous exposures and outcomes. In: Rothman K.J., and Greenland S. (Eds). Modern Epidemiology. 2nd ed. (1998), Lippincott-Raven Publishers, Philadelphia 317
26. Pouyssegur J., Dayan F., and Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (2006) 437-443